Cambrex Acquires Snapdragon Chemistry
Snapdragon Chemistry concentrates in API batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges.
Cambrex, a global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services, announced on Jan. 18 2023 that it has acquired Snapdragon Chemistry, a US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
“Today, we welcome our new colleagues from Snapdragon to Cambrex,” said Tom Loewald, CEO of Cambrex, in a press release. “With Snapdragon’s depth of scientific expertise in API process development, I’m certain our customers will see the benefits of this combination and be delighted to work with Snapdragon’s team.”
“I am extremely proud of what our team at Snapdragon has built over the years,” said Matt Bio, CEO of Snapdragon, in a press release. “With Cambrex, we have found an ideal home for our customers and employees, and I look forward to continued success as part of Cambrex.”
Snapdragon Chemistry concentrates in API batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges.
Cambrex is aiming to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing, especially with Snapdragon’s expertise in continuous flow manufacturing and complementing recent investments in continuous flow process development capabilities.
Source: Cambrex
